These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 16783994)

  • 21. Is a statin as part of a polypill the answer?
    Robinson JG
    Curr Atheroscler Rep; 2009 Jan; 11(1):15-22. PubMed ID: 19080723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-constituent cardiovascular pills (MCCP)--challenges and promises of population-based prophylactic drug therapy for prevention of heart attack.
    Jamieson MJ; Naghavi M
    Curr Pharm Des; 2007; 13(10):1069-76. PubMed ID: 17430169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The polypill as cardiovascular prophylactic: clinical trials].
    Sandli OK; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2014 Mar; 134(6):620-3. PubMed ID: 24670510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
    ; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
    Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do the current medical and economic times dictate the need for the "polypill"?
    Rifai L; Khan BV
    J Clin Hypertens (Greenwich); 2009 Dec; 11(12):775-6. PubMed ID: 20021541
    [No Abstract]   [Full Text] [Related]  

  • 26. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
    Blinc A; Poredos P
    Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].
    Scheen AJ; Lefèbvre PJ; Kulbertus H
    Rev Med Liege; 2003 Sep; 58(9):527-33. PubMed ID: 14626644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined use of polypill components in patients with type 2 diabetes mellitus.
    Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
    Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
    Sirois C; Poirier P; Moisan J; Grégoire JP
    Int J Cardiol; 2008 Sep; 129(2):172-9. PubMed ID: 18495263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.
    Sepanlou SG; Farzadfar F; Jafari E; Danaei G
    Arch Iran Med; 2012 Sep; 15(9):531-7. PubMed ID: 22924369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Polypill and type 2 diabetes.
    Gale E
    Diabet Med; 2004 Jan; 21 Suppl 1():8-10. PubMed ID: 15088929
    [No Abstract]   [Full Text] [Related]  

  • 37. The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera.
    Franco OH; Karnik K; Bonneux L
    Horm Metab Res; 2007 Sep; 39(9):627-31. PubMed ID: 17846968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canadian Hypertension Education Program. Brief overview of 2004 recommendations.
    Campbell N;
    Can Fam Physician; 2004 Oct; 50():1411-5. PubMed ID: 15526879
    [No Abstract]   [Full Text] [Related]  

  • 39. Physician support for a population-based pharmaceutical approach to cardiovascular prevention: not there yet.
    Huy C; Litaker D
    Prev Med; 2011 Jan; 52(1):18-9. PubMed ID: 21130110
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cardiovascular polypill in high risk patients].
    Lafeber M; Spiering W; Bots ML; de Valk V; Visseren FL; Grobbee DE
    Ned Tijdschr Geneeskd; 2011; 155(44):A3070. PubMed ID: 22067559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.